Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity

Recently developed genomics-based tools are allowing repositioning of Food and Drug Administration (FDA)-approved drugs as cancer treatments, which were employed to identify drugs that target cancer stem cells (CSCs) of breast cancer. Gene expression datasets of CSCs from six studies were subjected to connectivity map to identify drugs that may ameliorate gene expression patterns unique to CSCs. All-trans retinoic acid (ATRA) was negatively connected with gene expression in CSCs. ATRA reduced mammosphere-forming ability of a subset of breast cancer cells, which correlated with induction of apoptosis, reduced expression of SOX2 but elevated expression of its antagonist CDX2. SOX2/CDX2 ratio had prognostic relevance in CSC-enriched breast cancers. K-ras mutant breast cancer cell line enriched for CSCs was resistant to ATRA, which was reversed by MAP kinase inhibitors. Thus, ATRA alone or in combination can be tested for efficacy using SOX2, CDX2, and K-ras mutation/MAPK activation status as biomarkers of response.

[1]  Harikrishna Nakshatri,et al.  SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells With CD44+/CD24- Phenotype , 2010, BMC Cancer.

[2]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[3]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[4]  G. Hortobagyi,et al.  Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. , 2012, The Journal of clinical investigation.

[5]  Seung-Mo Hong,et al.  Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer , 2011, Clinical Cancer Research.

[6]  T. Misteli,et al.  In vitro generation of human cells with cancer stem cell properties , 2011, Nature Cell Biology.

[7]  A. Pavlick,et al.  A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer , 2011, Investigational New Drugs.

[8]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[9]  E. Lander,et al.  Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. , 2011, Cell stem cell.

[10]  Xiaolong Yang,et al.  The Egf Receptor‐Sox2‐Egf Receptor Feedback Loop Positively Regulates the Self‐Renewal of Neural Precursor Cells , 2009, Stem cells.

[11]  P. Pelicci,et al.  Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.

[12]  T. Tsukamoto,et al.  Cdx2 expression in pancreatic tumors: Relationship with prognosis of invasive ductal carcinomas. , 2004, Oncology reports.

[13]  D. Clegg,et al.  Memory in Induced Pluripotent Stem Cells: Reprogrammed Human Retinal‐Pigmented Epithelial Cells Show Tendency for Spontaneous Redifferentiation , 2010, Stem cells.

[14]  F. Bertucci,et al.  Retinoid signaling regulates breast cancer stem cell differentiation , 2009, Cell cycle.

[15]  K. Horwitz,et al.  Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts , 2008, Proceedings of the National Academy of Sciences.

[16]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[17]  R. McKay,et al.  Sox2 Acts through Sox21 to Regulate Transcription in Pluripotent and Differentiated Cells , 2012, Current Biology.

[18]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[19]  Ji‐you Li,et al.  Expression of Cdx2 and Hepatocyte Antigen in Gastric Carcinoma: Correlation with Histologic Type and Implications for Prognosis , 2005, Clinical Cancer Research.

[20]  I. Fariñas,et al.  Vascular niche factor PEDF modulates Notch-dependent stemness in the adult subependymal zone , 2009, Nature Neuroscience.

[21]  S. Badve,et al.  Breast-cancer stem cells-beyond semantics. , 2012, The Lancet. Oncology.

[22]  T. Schug,et al.  Opposing Effects of Retinoic Acid on Cell Growth Result from Alternate Activation of Two Different Nuclear Receptors , 2007, Cell.

[23]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[24]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[25]  Yan-hong Yu,et al.  Up-Regulation of Cadherin 17 and Down-Regulation of Homeodomain Protein CDX2 Correlate With Tumor Progression and Unfavorable Prognosis in Epithelial Ovarian Cancer , 2012, International Journal of Gynecologic Cancer.

[26]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[27]  T. Sørlie,et al.  Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity , 2012, Proceedings of the National Academy of Sciences.

[28]  Yan Li,et al.  Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug , 2013, Medical Oncology.

[29]  T. Schug,et al.  Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARβ/δ to RAR , 2008, Proceedings of the National Academy of Sciences.

[30]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[31]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[32]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[33]  J. Settleman,et al.  Activated Kras, but Not Hras or Nras, May Initiate Tumors of Endodermal Origin via Stem Cell Expansion , 2008, Molecular and Cellular Biology.

[34]  G. Landberg,et al.  Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms , 2012, Clinical Cancer Research.

[35]  D. Santini,et al.  Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells , 2012, Cell Death and Differentiation.

[36]  G. Sledge,et al.  Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. , 2000, Oncogene.

[37]  Harikrishna Nakshatri,et al.  CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis , 2006, Breast Cancer Research.

[38]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[39]  B. Leber,et al.  Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells , 2012, Cell.

[40]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[41]  D. van der Kooy,et al.  p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. , 2005, Genes & development.

[42]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Zoltan Szallasi,et al.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.

[44]  D. Larsimont,et al.  Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating–cancer stem cells: distinct, overlapping or same populations , 2011, Oncogene.

[45]  R. Sherwood,et al.  Transcriptional dynamics of endodermal organ formation , 2009, Developmental dynamics : an official publication of the American Association of Anatomists.

[46]  J. Balko,et al.  TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. , 2013, The Journal of clinical investigation.

[47]  Lang Li,et al.  Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. , 2006, Cancer research.

[48]  A. Pandiella,et al.  Sox2 expression in breast tumours and activation in breast cancer stem cells , 2012, Oncogene.

[49]  A. Zelent,et al.  Differentiation therapy of acute myeloid leukemia: past, present and future. , 2009, Current opinion in hematology.

[50]  S. Xuan,et al.  Igf1r as a therapeutic target in a mouse model of basal-like breast cancer , 2009, Proceedings of the National Academy of Sciences.

[51]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[52]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[53]  K. Hochedlinger,et al.  The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. , 2013, Cell stem cell.

[54]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[55]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[56]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[58]  K. Jensen,et al.  Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. , 2012, Cancer research.

[59]  G. Sledge,et al.  Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide , 2000, Oncogene.

[60]  P. Brown,et al.  Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.